Journal
LEUKEMIA & LYMPHOMA
Volume 55, Issue 12, Pages 2793-2800Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.898761
Keywords
Pharmacogenetics; polymorphism; methotrexate; RFC1; acute lymphoblastic leukemia; toxicity
Categories
Funding
- Fundamental Research Funds for the Central Universities of China [08143047]
Ask authors/readers for more resources
Methotrexate (MTX) is a key component of chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL), and enters the cell via active transport mediated by the reduced folate carrier (RFC1). A major single-nucleotide polymorphism of the RFC1 gene, G80A, which affects the activity of RFC1, may influence MTX toxicity in pediatric ALL. We collected all studies that investigated the association of RFC1 G80A polymorphism and MTX toxicity in pediatric ALL, and found inconsistency among their results. The aim of this meta-analysis was to summarize all of these studies in order to clarify the correlation between the RFC1 G80A polymorphism and MTX toxicity in pediatric ALL. A recessive model demonstrated no influence of the RFC1 G80A genotype on MTX toxicity. In conclusion, the RFC1 G80A polymorphism does not seem to be a good marker of MTX-related toxicity in pediatric ALL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available